Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects

Hironori Nagasaka, Hirokazu Tsukahara, Tohru Yorifuji, Takashi Miida, Kei Murayama, Tomoko Tsuruoka, Tomozumi Takatani, Masaki Kanazawa, Kunihiko Kobayashi, Yoshiyuki Okano, Masaki Takayanagi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Nitric oxide (NO) is synthesized from arginine and O2 by nitric oxide synthase (NOS). Citrulline, which is formed as a by-product of the NOS reaction, can be recycled to arginine by the 2 enzymes acting in the urea cycle: argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL). Although the complete urea cycle is expressed only in the liver, ASS and ASL are expressed in other organs including the kidney and vascular endothelium. To examine possible alterations of the NO pathway in urea cycle defects, we measured plasma concentrations of arginine and citrulline and serum concentrations of nitrite/nitrate (NOx-, stable NO metabolites) and asymmetric dimethylarginine (ADMA, an endogenous NOS inhibitor) in patients with congenital urea cycle disorders of 3 types: ornithine transcarbamylase (OTC) deficiency, ASS deficiency, and ASL deficiency. All were receiving oral arginine replacement at the time of this study. The same parameters were also measured in healthy subjects, who participated as controls. The OTC-deficient patients had significantly high NOx- and nonsignificantly high ADMA concentrations. Their NOx- was significantly positively correlated with arginine. The ASS-deficient patients had significantly low NOx- and significantly high ADMA concentrations. The ASL-deficient patients had normal NOx- and nonsignificantly high ADMA concentrations. In ASS-deficient and ASL-deficient patients, the NOx- was significantly inversely correlated with citrulline. These results suggest that NO synthesis is enhanced in OTC-deficient patients while receiving arginine but that NO synthesis remains low in ASS-deficient patients despite receiving arginine. They also suggest that endogenous NO synthesis is negatively affected by citrulline and ADMA in ASS-deficient and ASL-deficient patients. Although the molecular mechanisms remain poorly understood, we infer that the NO pathway might play a role in the pathophysiology related to congenital urea cycle disorders.

Original languageEnglish
Pages (from-to)278-282
Number of pages5
JournalMetabolism: Clinical and Experimental
Volume58
Issue number3
DOIs
Publication statusPublished - Mar 2009
Externally publishedYes

Fingerprint

Argininosuccinate Synthase
Argininosuccinate Lyase
Urea
Nitric Oxide
Arginine
Citrulline
Enzymes
Inborn Urea Cycle Disorder
Nitric Oxide Synthase
Ornithine Carbamoyltransferase
Argininosuccinic Aciduria
Citrullinemia
Ornithine Carbamoyltransferase Deficiency Disease
Time and Motion Studies
Vascular Endothelium
Nitrites
Nitrates
Healthy Volunteers
Kidney
Liver

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects. / Nagasaka, Hironori; Tsukahara, Hirokazu; Yorifuji, Tohru; Miida, Takashi; Murayama, Kei; Tsuruoka, Tomoko; Takatani, Tomozumi; Kanazawa, Masaki; Kobayashi, Kunihiko; Okano, Yoshiyuki; Takayanagi, Masaki.

In: Metabolism: Clinical and Experimental, Vol. 58, No. 3, 03.2009, p. 278-282.

Research output: Contribution to journalArticle

Nagasaka, H, Tsukahara, H, Yorifuji, T, Miida, T, Murayama, K, Tsuruoka, T, Takatani, T, Kanazawa, M, Kobayashi, K, Okano, Y & Takayanagi, M 2009, 'Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects', Metabolism: Clinical and Experimental, vol. 58, no. 3, pp. 278-282. https://doi.org/10.1016/j.metabol.2008.09.025
Nagasaka, Hironori ; Tsukahara, Hirokazu ; Yorifuji, Tohru ; Miida, Takashi ; Murayama, Kei ; Tsuruoka, Tomoko ; Takatani, Tomozumi ; Kanazawa, Masaki ; Kobayashi, Kunihiko ; Okano, Yoshiyuki ; Takayanagi, Masaki. / Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects. In: Metabolism: Clinical and Experimental. 2009 ; Vol. 58, No. 3. pp. 278-282.
@article{a5b4ef1e506443fa8089df5023f0e416,
title = "Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects",
abstract = "Nitric oxide (NO) is synthesized from arginine and O2 by nitric oxide synthase (NOS). Citrulline, which is formed as a by-product of the NOS reaction, can be recycled to arginine by the 2 enzymes acting in the urea cycle: argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL). Although the complete urea cycle is expressed only in the liver, ASS and ASL are expressed in other organs including the kidney and vascular endothelium. To examine possible alterations of the NO pathway in urea cycle defects, we measured plasma concentrations of arginine and citrulline and serum concentrations of nitrite/nitrate (NOx-, stable NO metabolites) and asymmetric dimethylarginine (ADMA, an endogenous NOS inhibitor) in patients with congenital urea cycle disorders of 3 types: ornithine transcarbamylase (OTC) deficiency, ASS deficiency, and ASL deficiency. All were receiving oral arginine replacement at the time of this study. The same parameters were also measured in healthy subjects, who participated as controls. The OTC-deficient patients had significantly high NOx- and nonsignificantly high ADMA concentrations. Their NOx- was significantly positively correlated with arginine. The ASS-deficient patients had significantly low NOx- and significantly high ADMA concentrations. The ASL-deficient patients had normal NOx- and nonsignificantly high ADMA concentrations. In ASS-deficient and ASL-deficient patients, the NOx- was significantly inversely correlated with citrulline. These results suggest that NO synthesis is enhanced in OTC-deficient patients while receiving arginine but that NO synthesis remains low in ASS-deficient patients despite receiving arginine. They also suggest that endogenous NO synthesis is negatively affected by citrulline and ADMA in ASS-deficient and ASL-deficient patients. Although the molecular mechanisms remain poorly understood, we infer that the NO pathway might play a role in the pathophysiology related to congenital urea cycle disorders.",
author = "Hironori Nagasaka and Hirokazu Tsukahara and Tohru Yorifuji and Takashi Miida and Kei Murayama and Tomoko Tsuruoka and Tomozumi Takatani and Masaki Kanazawa and Kunihiko Kobayashi and Yoshiyuki Okano and Masaki Takayanagi",
year = "2009",
month = "3",
doi = "10.1016/j.metabol.2008.09.025",
language = "English",
volume = "58",
pages = "278--282",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects

AU - Nagasaka, Hironori

AU - Tsukahara, Hirokazu

AU - Yorifuji, Tohru

AU - Miida, Takashi

AU - Murayama, Kei

AU - Tsuruoka, Tomoko

AU - Takatani, Tomozumi

AU - Kanazawa, Masaki

AU - Kobayashi, Kunihiko

AU - Okano, Yoshiyuki

AU - Takayanagi, Masaki

PY - 2009/3

Y1 - 2009/3

N2 - Nitric oxide (NO) is synthesized from arginine and O2 by nitric oxide synthase (NOS). Citrulline, which is formed as a by-product of the NOS reaction, can be recycled to arginine by the 2 enzymes acting in the urea cycle: argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL). Although the complete urea cycle is expressed only in the liver, ASS and ASL are expressed in other organs including the kidney and vascular endothelium. To examine possible alterations of the NO pathway in urea cycle defects, we measured plasma concentrations of arginine and citrulline and serum concentrations of nitrite/nitrate (NOx-, stable NO metabolites) and asymmetric dimethylarginine (ADMA, an endogenous NOS inhibitor) in patients with congenital urea cycle disorders of 3 types: ornithine transcarbamylase (OTC) deficiency, ASS deficiency, and ASL deficiency. All were receiving oral arginine replacement at the time of this study. The same parameters were also measured in healthy subjects, who participated as controls. The OTC-deficient patients had significantly high NOx- and nonsignificantly high ADMA concentrations. Their NOx- was significantly positively correlated with arginine. The ASS-deficient patients had significantly low NOx- and significantly high ADMA concentrations. The ASL-deficient patients had normal NOx- and nonsignificantly high ADMA concentrations. In ASS-deficient and ASL-deficient patients, the NOx- was significantly inversely correlated with citrulline. These results suggest that NO synthesis is enhanced in OTC-deficient patients while receiving arginine but that NO synthesis remains low in ASS-deficient patients despite receiving arginine. They also suggest that endogenous NO synthesis is negatively affected by citrulline and ADMA in ASS-deficient and ASL-deficient patients. Although the molecular mechanisms remain poorly understood, we infer that the NO pathway might play a role in the pathophysiology related to congenital urea cycle disorders.

AB - Nitric oxide (NO) is synthesized from arginine and O2 by nitric oxide synthase (NOS). Citrulline, which is formed as a by-product of the NOS reaction, can be recycled to arginine by the 2 enzymes acting in the urea cycle: argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL). Although the complete urea cycle is expressed only in the liver, ASS and ASL are expressed in other organs including the kidney and vascular endothelium. To examine possible alterations of the NO pathway in urea cycle defects, we measured plasma concentrations of arginine and citrulline and serum concentrations of nitrite/nitrate (NOx-, stable NO metabolites) and asymmetric dimethylarginine (ADMA, an endogenous NOS inhibitor) in patients with congenital urea cycle disorders of 3 types: ornithine transcarbamylase (OTC) deficiency, ASS deficiency, and ASL deficiency. All were receiving oral arginine replacement at the time of this study. The same parameters were also measured in healthy subjects, who participated as controls. The OTC-deficient patients had significantly high NOx- and nonsignificantly high ADMA concentrations. Their NOx- was significantly positively correlated with arginine. The ASS-deficient patients had significantly low NOx- and significantly high ADMA concentrations. The ASL-deficient patients had normal NOx- and nonsignificantly high ADMA concentrations. In ASS-deficient and ASL-deficient patients, the NOx- was significantly inversely correlated with citrulline. These results suggest that NO synthesis is enhanced in OTC-deficient patients while receiving arginine but that NO synthesis remains low in ASS-deficient patients despite receiving arginine. They also suggest that endogenous NO synthesis is negatively affected by citrulline and ADMA in ASS-deficient and ASL-deficient patients. Although the molecular mechanisms remain poorly understood, we infer that the NO pathway might play a role in the pathophysiology related to congenital urea cycle disorders.

UR - http://www.scopus.com/inward/record.url?scp=59649120881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649120881&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2008.09.025

DO - 10.1016/j.metabol.2008.09.025

M3 - Article

VL - 58

SP - 278

EP - 282

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 3

ER -